In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews (10/06)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Women's Health: A Growing Market for Diagnostic Players, includes profiles of Diamics, Onconix, RCP Diagnostics and Valeo Medical. Plus these Start-Ups Across Health Care: Corindus, Gynesonics, NovaSterilis and Zogenix.

You may also be interested in...



Coronavirus Notebook: Heterologous Vaccine Study Shows Positive Results, UK Offers Earlier Second Dose To Vulnerable People

The European Medicines Agency has extended the time that Cominarty can spend in a fridge after defrosting and could this week issue advice to member states on sotrovimab for use in COVID-19 patients. Norway’s BerGenBio has published top-line data from a Phase II trial of of bemcentinib, and IcanoMAB has outlined the potential of its anti-IL-1R7 antibody.

Yes Or No? Decisions Due On New EU Drug Applications

Myovant, Bayer and Rhythm Pharmaceuticals are among the companies that could soon learn whether the European Medicines Agency thinks their drugs are fit for approval.

Drug Pricing Shake Up Likely In Germany

The umbrella organization for public insurers is also expected to publish its own suggestions on how to cut spending on pharmaceuticals, including interim prices for conditionally approved drugs.

Related Companies

UsernamePublicRestriction

Register

IV002838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel